Skip to content

Capricor Therapeutics CAPR Interest Expense, Nonoperating

Interest Expense, Nonoperating at other companies

Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$761.43K
Cal-Maine Foods logo
Cal-Maine FoodsCALM
$153K+11.5%
Quantum Computing Inc. logo
Quantum Computing Inc.QUBT
$171K+195%
ADMA Biologics logo
ADMA BiologicsADMA
$2.1M+6.3%
HTF
Heartflow, Inc. Common StockHTFL
$3K-99.9%
Ondas, Inc.
 logo
Ondas, Inc. ONDS
$338K-91.3%

Other financials

Income statement

See full
Revenue--100%
Operating income-$36.8M-47.2%
Net income-$33.9M-39.2%
EPS (diluted)-$0.59-11.3%

Balance sheet

See full
Cash & equivalents$105.4M+266%
Total debt$14.8M+1,083%
Total equity$278.7M+118%
Total assets$326.3M+112%

Cash flow

See full
Operating cash flow-$29.3M-355%
CapEx$5.1M+472%
Free cash flow-$34.4M-369%

Valuation

See full
Market cap$1.71B+303%
Enterprise value$1.62B+308%

Profitability

See full
Operating margin-778.8%-1,038pp
Net margin-736.6%-981pp
FCF margin-563.9%-954pp

Returns & leverage

See full
Return on equity-56.4%-11.3pp
Debt / equity0.1×0.0×
Current ratio8.4×+1.9×

Where this comes from

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.

The official record: Capricor Therapeutics’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Capricor Therapeutics's interest expense, nonoperating.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Capricor Therapeutics's interest expense, nonoperating?
Capricor Therapeutics (CAPR) reported interest expense, nonoperating of $761.43K in Q4 2025.
What does interest expense, nonoperating mean?
This captures interest costs incurred on debt obligations that are not directly related to the company's core operating activities. It reflects the cost of capital and the financial burden of the company's debt structure. High levels of nonoperating interest expense can indicate significant leverage and potential liquidity risks for a development-stage firm.